Oncology and Cancer Research

This series will focus on noncoding RNAs to serve as biomarkers for diagnosis, prognosis, as well as therapy in both malignant and non-malignant disorders.

Submission Deadline: 01 October 2022

This Special Issue gives space to studies that highlight lncRNAs and circRNAs as possible markers of prognosis, diagnosis, drug resistance and metastasis processes in solid and hematopoietic tumors.

Submissions Deadline: 31 December 2022

Here we present a series of articles illustrating the current disparities in cancer incidence and mortality and suggesting what can be done to relieve these inequities.

BMC Cancer, BMC Microbiology and Microbiome invite submissions to the ‘Microbiome and Cancer’ collection.

This Journal of Hematology & Oncology series calls for clinical studies on novel agents for cancers and blood disorders. 

This open Collection on Liquid Biopsies features developments in technology that allow the detection of tumour-relevant entities in blood samples, including circulating tumour DNA, RNA, extracellular vesicles, tumour cells and tumour-educated immune cells.

This open Collection on Metastasis highlights the ongoing challenges in the field and research being undertaken to more thoroughly understand models of metastasis, disrupt the metastatic cascade, and improve treatment outcomes for patients

The ‘Precision Oncology & Supportive Care’ collection considers Articles and Reviews concerning the side effects of genomic-guided medicine, pharmacogenomics, multiomics, and strategies to mitigate these toxicities.

A paradox in tumor immunity is the co-existing of growing tumors with circulating or tissue-infiltrating tumor-reactive T cells. 

Cancer therapy using chimeric antigen receptor (CAR)-T-cells is one of the most exciting recent developments in cancer therapy.

Metastatic cancer is ultimately resistant to virtually all systemic therapies and continues to kill more than 10 million people per year around the world.

A new University of Cambridge-led study will investigate the feasibility of developing a full kidney cancer screening clinical trial.

Alexander Seager discusses the COLO-DETECT study.

Christina Uwins and Simon Butler-Manuel discuss the MIRRORS study.

Dr Vinton Cheng and Dr Amy Kwan discuss the PRIMROSE audit.